The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches

被引:40
作者
Weiner, D. M. [1 ]
Durgin, Joseph S. [1 ]
Wysocka, Maria [1 ]
Rook, Alain H. [1 ]
机构
[1] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
CTCL; cutaneous T cell lymphoma; dermatologic oncology; drug response; immune deficiency; immunopathogenesis; immunotherapy; mycosis fungoides; Sezary syndrome;
D O I
10.1016/j.jaad.2020.12.026
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
In the past few decades, immunotherapy has emerged as an effective therapeutic option for patients with cutaneous T cell lymphoma (CTCL). CTCL is characterized by progressive impairment of multiple arms of the immune system. Immunotherapy targets these deficits to stimulate a more robust antitumor response, thereby both clearing the malignant T cells and repairing the immune dysfunction. By potentiating rather than suppressing the immune system, immunotherapy can result in longer treatment responses than alternatives such as chemotherapy. In recent years, advances in our understanding of the pathogenesis of CTCL have led to the development of several new agents with promising efficacy profiles. The second article in this continuing medical education series describes the current immunotherapeutic options for treatment of CTCL, with a focus on how they interact with the immune system and their treatment outcomes in case studies and clinical trials. We will discuss established CTCL immunotherapies, such as interferons, photopheresis, and retinoids; emerging therapies, such as interleukin-12 and Toll-like receptor agonists; and new approaches to targeting tumor antigens and checkpoint molecules, such as mogamulizumab, anti-programmed cell death protein 1, anti-CD47, and chimeric antigen receptor T cell therapy. We also describe the principles of multimodality immunotherapy and the use of total skin electron beam therapy in such regimens.
引用
收藏
页码:597 / 604
页数:8
相关论文
共 63 条
  • [21] Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
    Kim, Youn H.
    Girardi, Michael
    Duvic, Madeleine
    Kuzel, Timothy
    Link, Brian K.
    Brown, Lauren Pinter
    Rook, Alain H.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (06) : 975 - 983
  • [22] INTERFERONS IN THE TREATMENT OF HUMAN CANCER
    KIRKWOOD, JM
    ERNSTOFF, MS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (04) : 336 - 352
  • [23] Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis
    Knobler, Robert
    Duvic, Madeleine
    Querfeld, Christiane
    Straus, David
    Horwitz, Steven
    Zain, Jasmine
    Foss, Francine
    Kuzel, Timothy
    Campbell, Kim
    Geskin, Larisa
    [J]. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2012, 28 (05) : 250 - 257
  • [24] Anti-CD7 immunotherapy is mediated by cytotoxic CD107a+IFN-γ- NK cells and can be potentiated by interferon-α in cutaneous lymphoma
    Kruglov, Oleg
    Johnson, Lisa D. S.
    Uger, Robert A.
    Wong, Mark
    Wu, Xuesong
    Hwang, Sam T.
    Akilov, Oleg E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 119 : S33 - S33
  • [25] Iron deficiency anemia associated with extracorporeal photopheresis: A retrospective analysis
    Kuhn, Alexis K.
    Bartoo, Gabriel T.
    Dierkhising, Ross A.
    Mara, Kristin C.
    Winters, Jeffrey L.
    Patnaik, Mrinal M.
    Gastineau, Dennis A.
    Adamski, Jill
    Merten, Julianna A.
    [J]. JOURNAL OF CLINICAL APHERESIS, 2019, 34 (06) : 666 - 671
  • [26] EFFECTIVENESS OF INTERFERON ALFA-2A COMBINED WITH PHOTOTHERAPY FOR MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME
    KUZEL, TM
    ROENIGK, HH
    SAMUELSON, E
    HERRMANN, JJ
    HURRIA, A
    RADEMAKER, AW
    ROSEN, ST
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 257 - 263
  • [27] Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
    Lesokhin, Alexander M.
    Ansell, Stephen M.
    Armand, Philippe
    Scott, Emma C.
    Halwani, Ahmad
    Gutierrez, Martin
    Millenson, Michael M.
    Cohen, Adam D.
    Schuster, Stephen J.
    Lebovic, Daniel
    Dhodapkar, Madhav
    Avigan, David
    Chapuy, Bjoern
    Ligon, Azra H.
    Freeman, Gordon J.
    Rodig, Scott J.
    Cattry, Deepika
    Zhu, Lili
    Grosso, Joseph F.
    Garelik, M. Brigid Bradley
    Shipp, Margaret A.
    Borrello, Ivan
    Timmerman, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) : 2698 - +
  • [28] Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series
    Lewis, Daniel J.
    Byekova, Yevgeniya A.
    Emge, Drew A.
    Duvic, Madeleine
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (06) : 567 - 569
  • [29] Clinical and in vitro resistance to bexarotene in adult T-cell leukemia:: loss of RXR-α receptor
    Lin, Julie H.
    Kim, Ellen J.
    Bansal, Anand
    Seykora, John
    Richardson, Stephen K.
    Cha, Xian-Yuan
    Zafar, Sarosh
    Nasta, Sunita
    Wysocka, Maria
    Benoit, Bernice
    Rook, Alain H.
    Fakharzadeh, Steven S.
    [J]. BLOOD, 2008, 112 (06) : 2484 - 2488
  • [30] Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
    Locke, Frederick L.
    Ghobadi, Armin
    Jacobson, Caron A.
    Miklos, David B.
    Lekakis, Lazaros J.
    Oluwole, Olalekan O.
    Lin, Yi
    Braunschweig, Ira
    Hill, Brian T.
    Timmerman, John M.
    Deol, Abhinav
    Reagan, Patrick M.
    Stiff, Patrick
    Flinn, Ian W.
    Farooq, Umar
    Goy, Andre
    McSweeney, Peter A.
    Munoz, Javier
    Siddiqi, Tanya
    Chavez, Julio C.
    Herrera, Alex F.
    Bartlett, Nancy L.
    Wiezorek, Jeffrey S.
    Navale, Lynn
    Xue, Allen
    Jiang, Yizhou
    Bot, Adrian
    Rossi, John M.
    Kim, Jenny J.
    Go, William Y.
    Neelapu, Sattva S.
    [J]. LANCET ONCOLOGY, 2019, 20 (01) : 31 - 42